Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 11/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 10/20 | 0.47 |
| ▸ | MPL | P40238 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888242 | 0.88 | FEN1 (0.49) | FEN1ALOX5APMPL | |
| SCHEMBL1894022 | 0.87 | RECQL (0.47) | FEN1ALOX5APMPLKMT2AMAPT | |
| SCHEMBL2388395 | 0.81 | EGFR (0.44) | FEN1ALOX5APMPL | |
| SCHEMBL2390339 | 0.81 | ALOX5AP (0.40) | FEN1ALOX5APMPLMAPTIDO1 | |
| SCHEMBL1886977 | 0.80 | MPL (0.46) | FEN1ALOX5APMPLIDO1 | |
| SCHEMBL1656041 | 0.77 | ALOX5AP (0.49) | FEN1ALOX5AP | |
| SCHEMBL1891048 | 0.75 | FEN1 (0.49) | FEN1ALOX5APMPL | |
| SCHEMBL27805538 | 0.75 | FEN1 (0.44) | FEN1ALOX5APMPL | |
| SCHEMBL1885931 | 0.75 | FEN1 (0.46) | FEN1ALOX5APMPLKMT2A | |
| SCHEMBL1884677 | 0.74 | ALOX5AP (0.47) | FEN1ALOX5APMPLMAPTGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-05-05 | — | — | US | claimed |
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA5, CHRNA3, CHRM3 | FEN1 4851/4885ALOX5AP 2582/4885MPL 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.